已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective

医学 Evolocumab公司 以兹提米比 他汀类 PCSK9 急性冠脉综合征 内科学 心脏病学 心肌梗塞 质量调整寿命年 成本效益 胆固醇 脂蛋白 低密度脂蛋白受体 风险分析(工程) 载脂蛋白A1
作者
Xiaoyu Xi,Xin Wang,Wenwen Xie,Jia Yu,Santiago Zuluaga Sanchez,Laura Martínez,Quanming Zhao
出处
期刊:Cardiovascular Drugs and Therapy [Springer Science+Business Media]
卷期号:37 (5): 905-916 被引量:13
标识
DOI:10.1007/s10557-021-07276-x
摘要

PurposeTo assess the cost-effectiveness of evolocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, compared with ezetimibe, both added to background statin therapy in patients with recent acute coronary syndrome (ACS) events (in the past 12 months) and low-density lipoprotein cholesterol (LDL-C) levels ≥ 100 mg/dL in China.MethodsA health economic evaluation was performed from a Chinese healthcare perspective, using a Markov model over a lifetime horizon based on a baseline cardiovascular (CV) event rate from claims database data and efficacy from the FOURIER trial. The health benefit was reflected in the decrease of LDL-C level, which led to a decrease of cardiovascular events. The costs of cardiovascular events and the utility value of each health state were derived from the published literature. Sensitivity analyses were conducted to evaluate the effects of uncertainty in parameters and the robustness of the model. The cost-effectiveness of evolocumab was also explored in patients with recent myocardial infarction (MI), at very high risk (VHR) of atherosclerotic cardiovascular disease (ASCVD), and homozygous familiar hypercholesterolemia (HoFH).ResultsIn patients with recent ACS, evolocumab was associated with incremental quality-adjusted life-years (QALYs) of 1.33 and incremental costs of 115,782 yuan versus ezetimibe, both with background statin therapy, resulting in an incremental cost-effectiveness ratio (ICER) of 87,050 yuan per QALY gained. The probability of evolocumab + statins being cost-effective at a threshold of 217,341 yuan (three times per capita GDP, 2020), compared with ezetimibe + statins, was 100% in patients with recent ACS, recent MI, VHR ASCVD, and HoFH.ConclusionCompared with ezetimibe + statins, the combination of evolocumab + statins was found to be cost-effective at a threshold of 217,341 yuan (three times per capita GDP, 2020) in patients with recent ACS events in China.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
梁33完成签到,获得积分10
刚刚
刚刚
完美的睿渊完成签到,获得积分10
2秒前
2秒前
gqz完成签到,获得积分20
3秒前
maining完成签到,获得积分10
4秒前
huanhuan发布了新的文献求助10
4秒前
5秒前
6秒前
Milton_z完成签到 ,获得积分0
8秒前
车访枫发布了新的文献求助10
8秒前
12秒前
归尘发布了新的文献求助10
12秒前
15秒前
16秒前
16秒前
幽默果汁完成签到 ,获得积分10
16秒前
huanhuan完成签到,获得积分10
16秒前
华仔完成签到 ,获得积分10
16秒前
17秒前
热情善斓完成签到,获得积分10
18秒前
小二郎的应助被苹果思天采纳,获得10
18秒前
Maestro_S的应助被车访枫采纳,获得10
20秒前
21秒前
21秒前
22秒前
科研牛马完成签到,获得积分10
23秒前
24秒前
磊4165564发布了新的文献求助10
28秒前
30秒前
35秒前
曼波完成签到 ,获得积分10
35秒前
烟花的应助被可靠的公爵熊采纳,获得10
35秒前
小番茄完成签到 ,获得积分10
36秒前
wwwww完成签到 ,获得积分10
37秒前
李大海发布了新的文献求助10
39秒前
缥缈的凝丹完成签到,获得积分10
43秒前
时鸢完成签到,获得积分10
44秒前
45秒前
46秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158533
求助须知:如何正确求助?哪些是违规求助? 9554296
关于积分的说明 21718786
捐赠科研通 7747941
什么是DOI,文献DOI怎么找? 3427015
关于科研通互助平台的介绍 2551811
邀请新用户注册赠送积分活动 2471194